Illumina, Inc. (NASDAQ:ILMN) insider Francis A. Desouza sold 3,000 shares of the business’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $345.90, for a total transaction of $1,037,700.00. Following the completion of the transaction, the insider now owns 65,443 shares in the company, valued at $22,636,733.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ ILMN opened at $334.21 on Thursday. Illumina, Inc. has a 1-year low of $207.51 and a 1-year high of $372.61. The stock has a market capitalization of $49.13 billion, a price-to-earnings ratio of 57.23, a P/E/G ratio of 2.48 and a beta of 1.09. The company has a quick ratio of 2.24, a current ratio of 2.46 and a debt-to-equity ratio of 0.24.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.26 by $0.26. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The company had revenue of $853.00 million during the quarter, compared to the consensus estimate of $825.65 million. During the same period in the previous year, the firm posted $1.11 earnings per share. The company’s revenue was up 19.5% on a year-over-year basis. On average, equities research analysts anticipate that Illumina, Inc. will post 5.75 earnings per share for the current year.

A number of equities analysts have commented on the stock. ValuEngine lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Cowen boosted their price target on shares of Illumina from $315.00 to $400.00 and gave the company a “positive” rating in a research report on Thursday, September 6th. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Barclays boosted their price target on shares of Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research report on Wednesday, October 24th. Finally, BidaskClub upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 1st. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $330.94.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Belpointe Asset Management LLC bought a new stake in shares of Illumina during the third quarter worth approximately $155,000. Vanguard Group Inc. raised its stake in shares of Illumina by 1.8% during the third quarter. Vanguard Group Inc. now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after buying an additional 188,516 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Illumina by 6.8% during the third quarter. Legal & General Group Plc now owns 657,774 shares of the life sciences company’s stock worth $241,442,000 after buying an additional 41,978 shares during the last quarter. Kepos Capital LP raised its stake in shares of Illumina by 394.5% during the third quarter. Kepos Capital LP now owns 12,037 shares of the life sciences company’s stock worth $4,418,000 after buying an additional 9,603 shares during the last quarter. Finally, Financial Enhancement Group LLC bought a new stake in shares of Illumina during the third quarter worth approximately $400,000. 88.91% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/francis-a-desouza-sells-3000-shares-of-illumina-inc-ilmn-stock/2663928.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Story: Put Option

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.